论文部分内容阅读
目的观察131I治疗ATD治疗后白细胞减少Graves病的疗效及安全性。资料与方法在应用生白细胞治疗的基础上,对145例ATD治疗后出现白细胞减少的Graves病患者,进行131I治疗,观察治疗前、治疗后2周、1月、3月、6月的白细胞变化及治疗后6月的疗效。结果131I治疗2周及1个月后外周血白细胞与治疗前比较无显著性统计学差异(P>0.05),131I治疗3个月及6个月后外周血细胞与治疗前比较有显著性统计学差异(P<0.01),治疗3个月及6个月细胞明显高于治疗前。131I一次治疗6月后一次治疗痊愈率60%,总有效率为97.9%,甲低发生率15.8%。结论131I治疗ATD治疗后出现白细胞减少的Graves病安全有效,治疗前及治疗后1月持续升白细胞药物治疗能提高131I治疗的安全性
Objective To observe the efficacy and safety of 131I in treating leukemia after Graves’ disease (ATD). Materials and Methods Based on the application of leukocyte therapy, 145 patients with Graves disease with leukopenia after ATD were treated with 131I, and the changes of leukocyte before treatment, 2 weeks after treatment, 1 month, 3 months and 6 months after treatment were observed And after 6 months of treatment. Results There was no significant difference in peripheral blood leukocytes after 131I treatment for 2 weeks and 1 month (P> 0.05). There was a significant statistical difference between the peripheral blood cells after 131I treatment for 3 months and 6 months (P <0.01). The cells at 3 months and 6 months after treatment were significantly higher than those before treatment. After a treatment of 131I a treatment of six months after the cure rate of 60%, the total effective rate was 97.9%, a hypothyroidism rate of 15.8%. Conclusion 131I treatment of leukopenia after ATD treatment of Graves disease is safe and effective, before treatment and after 1 month of continuous leukocyte drug therapy can improve the safety of 131I treatment